drug development
New ‘tech’ on the block: The critical role of new tech in advancing patient autonomy and drug development
Dr Andrew Rut, CEO and founder of MyMeds&Me, examines the critical role of new technology, in the form of smart pharmaceuticals and blockchain, in advancing patient autonomy and drug development. more
French connection: NDA Group opens Parisian office
NDA Group, European drug development consultancy, has opened a new office in Paris, France, to serve its growing customer base in the country and continue its global expansion. more
Attitude toward safety in cancer drug development needs to change, says ApconiX co-founder
A co-founder of the company ApconiX, based in Alderley Park, has revealed his view that attitude towards safety in pre-clinical cancer drug development needs to change. more
New homes for old drugs: Could repurposing offer a financial solution?
Health systems are facing the biggest challenge in their existence: financial sustainability fuelled by the costs of prescription drugs. Here, Marisa Miraldo, associate professor at Imperial College Business School, goes into more detail… more
Evgen Pharma and King’s collaborate to advance therapy for ischaemic stroke
Evgen Pharma, a clinical-stage drug development company, has announced its collaboration with King’s College London to advance its lead product candidate as a therapy for ischaemic stroke. more
ApconiX sees sales boost as demand for drug safety expertise increases
A nonclinical safety company that works with the pharma sector based in Alderley Park, ApconiX, has increased sales by five-fold as a result of the industry’s demand for drug safety expertise. more
Size matters — revealing how small and flexible means fast and profitable in pharma packaging
Gregor Deutschle, global business development manager for SCHOTT, speaks about how small and flexible means fast and profitable in pharma packaging and he reveals what this shift in manufacturing means for the industry and consumers. more
New drug for paediatric nonverbal disorder developed
Biotechnology acceleration company, Q BioMed, has announced its successful development of a new and proprietary analogue of QBM-001 in partnership with Sphaera Pharma for paediatric nonverbal disorder. more
Partnership in early drug development services extended
XenoGesis and Juniper Pharma Services have extended their partnership in early drug development services by adding GastroPlus, PBPK modelling and simulation software. more
Report on collaborative R&D in drug development released
Global health science marketing and communications firm, SCORR Marketing, has released a new study, in partnership with Applied Clinical Trials, evaluating the extent to which collaborations occur in the life sciences what influences them more
Multi-year agreement signed focusing on immune tolerance
German biotechnology company, Topas Therapeutics, has signed a multi-year agreement with Eli Lilly and Company, which will see the companies collaborate to generate drug candidates in the field of antigen specific tolerance induction. more
Key milestone met in project aimed at accelerating drug development
A new platform to accelerate drug development has been created through the collaboration of Juniper Pharma Services (a subsidiary of Juniper Pharmaceuticals), and CrystecPharma in the Advanced Manufacturing Supply Chain Initiative (AMSCI). more
Certara to be sold, but Arsenal retaining minority ownership stake
Arsenal Capital Partners has announced it is selling its portfolio company, Certara, to EQT VII Fund for $850 million, although, as a part of the deal, it will retain a minority ownership stake. more
Patheon invests in key sites to support continued growth
Global provider of drug development and delivery solutions to the pharmaceutical sector, Patheon, has revealed it is anticipating to invest approximately $45 million at key sites worldwide to meet growing customer demand more
Innovation is key for pharmaceutical companies in a harsh market environment, says report
Fewer than two in 10 medicines exceed the average pharmaceutical R&D cost required to bring a drug to market when the risks of failure to reach market approval are factored in, according to GBI Research. more
In the CAR-T: CTL019 receives breakthrough therapy designation
The FDA has granted breakthrough therapy designation to Novartis’ investigational chimeric antigen receptor T cell (CAR-T) therapy, CTL019 more
Stats may speed up cancer drug development
Recently published research from the Massachusetts Institute of Technology (MIT) and Mayo Clinic proposes a mathematical framework that may accelerate drug development. more
Rheumatoid arthritis pipeline drugs unlikely to address unmet needs
According to the latest report from GlobalData, pipeline agents in the rheumatoid arthritis space are unlikely to address unmet needs by 2025. more
Trials and tribulations: Protecting pharma IP
What role will IP management play in protecting pharmaceutical companies in the future? Casey Fowler, VP of IP Search, CPA Global writes. more
Winning formula: Searching for the right formulation for oral solid dose applications
Anil Kane, Ph.D., MBA, executive director, global head of formulation sciences, pharmaceutical development services at Patheon on finding the right formulation for oral solid dose applications more
